deucravacitinib,anifrolumab,belimumab,litifilimab,iberdomide,cyclophosphamide
astrazeneca,bms,biogen,gsk
['anifro', 'litifilimab', 'iberdomide', 'anifrolumab', 'deucra', 'belimumab', 'cyclophosphamide', 'lupus']
2023 sle recommendations lower gc dose (5 mg instead of 7.5) early use of biologics for corticosparing cyclophosphamide if life-threatening mmf: new in hemato manif lupus nephritis: vcl vs bel??? maintain trt for 3 years then taper, except hcq #eular2023 nz 
Annals of the Rheumatic Diseases (#1 research journal in Rheumatology) & RMD Open are the official @EULAR_ORG journals. High quality, peer reviewed research.